Brief: Theravet FY Net Loss Widens To EUR 1.3 Million

Theravet SA

06/04/2022 06:45

April 6 (Reuters) - Theravet SA  ALVET.PA :
    * FY REVENUE EUR 12,348 VERSUS EUR 0 YEAR AGO
    * STRONG CASH POSITION OF EUR 5.63M AT DECEMBER 31, 2021
GIVING
TWO YEARS OF FINANCIAL VISIBILITY
    * POSITIVE SAFETY AND EFFICACY RESULTS FOR BIOCERA-VET®
(ARTHRODESIS AND CANINE OSTEOSARCOMA) AND VISCO-VET® (CANINE
OSTEOARTHRITIS)
    * FY EBITDA LOSS EUR 1.2 MILLION VERSUS EUR LOSS OF EUR 0.4
MILLION YEAR AGO
    * FY NET LOSS EUR 1.3 MILLION VERSUS LOSS OF EUR 0.4 MILLION
YEAR
AGO
    * IN 2022, THE COMPANY INTENDS TO CONTINUE THE DEVELOPMENT
OF ITS
VARIOUS ASSETS AND ACCELERATE THE RAMPING UP OF THE
COMMERCIALIZATION OF BIOCERA-VET
    * INITIATION OF THE PIVOTAL EUROPEAN MULTICENTRIC CLINICAL
EVALUATING VISCO-VET® IN CANINE OSTEOARTHRITIS IN POLAND AND
PORTUGAL ANTICIPATED IN FIRST SEMESTER 2022
    * LAUNCH OF BIOCERA-VET® LINE IN THE UNITED STATES OF
AMERICA AND
IN GERMANY (THE BIGGEST COMPANION ANIMAL MARKET IN EUROPE),
RESPECTIVELY DURING THE FIRST AND SECOND HALF OF 2022

Source text for Eikon:  ID:nBw3RgK3na 
Further company coverage:  ALVET.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))